Profile data is unavailable for this security.
About the company
Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system, respiratory and metabolic diseases. Its pipeline includes two drug candidates, RP5063 (brilaroxazine) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).
- Revenue in USD (TTM)0.00
- Net income in USD-39.26m
- Incorporated2020
- Employees15.00
- LocationReviva Pharmaceuticals Holdings, Inc.10080 N Wolfe Road, Suite Sw3-200CUPERTINO 95014United StatesUSA
- Phone+1 (408) 501-8881
- Fax+1 (408) 904-6270
- Websitehttps://revivapharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Incannex Healthcare Inc | 163.39k | -13.70m | 44.13m | -- | -- | 2.34 | -- | 270.07 | -0.3806 | -0.3806 | 0.0003 | 1.19 | 0.0038 | -- | 0.0554 | -- | -31.42 | -54.94 | -32.90 | -59.47 | -- | -- | -8,386.19 | -1,033.07 | -- | -- | 0.00 | -- | 61.92 | 3.38 | -24.35 | -- | 54.12 | -- |
| IN8BIO, Inc. | 0.00 | -31.04m | 44.90m | 31.00 | -- | 2.52 | -- | -- | -0.9154 | -0.9154 | 0.00 | 0.4049 | 0.00 | -- | -- | 0.00 | -123.61 | -74.18 | -145.63 | -84.42 | -- | -- | -- | -- | -- | -- | 0.0556 | -- | -- | -- | -5.21 | -- | -4.54 | -- |
| Ocuphire Pharma Inc | 19.01m | -11.30m | 44.98m | 14.00 | -- | 0.945 | -- | 2.37 | -0.4867 | -0.4867 | 0.8366 | 1.84 | 0.391 | -- | 4.52 | 1,357,929.00 | -23.24 | -58.31 | -25.89 | -65.94 | -- | -- | -59.44 | -137.92 | -- | -9.73 | 0.00 | -- | -52.20 | -- | -155.83 | -- | -- | -- |
| Immuneering Corp | 0.00 | -54.18m | 45.67m | 65.00 | -- | 0.5801 | -- | -- | -1.86 | -1.86 | 0.00 | 2.65 | 0.00 | -- | -- | 0.00 | -55.37 | -- | -58.58 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -5.86 | -- | -- | -- |
| NextCure Inc | 0.00 | -63.73m | 46.16m | 82.00 | -- | 0.4648 | -- | -- | -2.29 | -2.29 | 0.00 | 3.55 | 0.00 | -- | -- | 0.00 | -45.05 | -22.59 | -47.72 | -23.54 | -- | -- | -- | -964.96 | -- | -- | 0.00 | -- | -- | -- | 16.07 | -- | -23.17 | -- |
| Aadi Bioscience Inc | 23.84m | -68.83m | 47.02m | 75.00 | -- | 0.5198 | -- | 1.97 | -2.55 | -2.55 | 0.8848 | 3.68 | 0.1692 | 0.6021 | 4.54 | 267,865.20 | -48.86 | -50.25 | -56.39 | -56.15 | 87.70 | -- | -288.72 | -473.97 | 4.86 | -- | 0.00 | -- | 60.06 | 3.85 | -8.68 | -- | 153.54 | -- |
| Carmell Corp | 0.00 | -16.88m | 47.27m | 9.00 | -- | 2.13 | -- | -- | -1.53 | -1.46 | 0.00 | 1.07 | -- | -- | -- | 0.00 | -- | -- | -- | -- | 58.60 | -- | -- | -- | -- | -194.46 | 0.0495 | -- | -- | -- | -75.70 | -- | -- | -- |
| Reviva Pharmaceuticals Holdings, Inc. | 0.00 | -39.26m | 47.74m | 15.00 | -- | 8.35 | -- | -- | -1.66 | -1.66 | 0.00 | 0.2048 | 0.00 | -- | -- | 0.00 | -184.22 | -- | -507.01 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -38.92 | -- | -- | -- |
| Correlate Energy Corp | 7.56m | -12.79m | 48.15m | 19.00 | -- | -- | -- | 6.37 | -0.3554 | -0.3554 | 0.21 | -0.0877 | 2.22 | -- | 13.19 | 398,051.60 | -375.16 | -315.47 | -- | -- | 18.27 | 15.42 | -169.09 | -201.03 | -- | -0.7239 | 8.30 | -- | 122.20 | 46.12 | -78.54 | -- | -- | -- |
| Benson Hill Inc | 359.83m | -132.72m | 48.23m | 270.00 | -- | 0.7167 | -- | 0.134 | -0.7033 | -0.7082 | 1.90 | 0.3174 | 1.13 | 9.80 | 20.67 | 1,332,689.00 | -41.85 | -- | -49.16 | -- | 5.38 | 3.18 | -36.88 | -40.73 | 2.02 | -2.12 | 0.183 | -- | 24.16 | 156.43 | -11.58 | -- | 63.78 | -- |
| Dyadic International Inc | 2.26m | -7.85m | 48.53m | 7.00 | -- | 10.73 | -- | 21.52 | -0.2724 | -0.2724 | 0.0783 | 0.1547 | 0.1769 | -- | 4.51 | 322,197.20 | -61.58 | -36.82 | -73.50 | -39.85 | 38.24 | 22.47 | -348.00 | -410.16 | -- | -- | 0.5634 | -- | -1.07 | 17.48 | 30.20 | -- | -- | -- |
| Gain Therapeutics Inc | 55.18k | -22.27m | 48.56m | 29.00 | -- | 3.47 | -- | 880.03 | -1.74 | -1.74 | 0.0042 | 0.7761 | 0.0026 | -- | 0.2544 | 1,902.76 | -104.28 | -- | -132.41 | -- | -- | -- | -40,354.33 | -13,827.07 | -- | -- | 0.0432 | -- | -60.62 | 21.77 | -26.59 | -- | 13.96 | -- |
| Clene Inc. | 620.00k | -48.81m | 49.52m | 82.00 | -- | 11.61 | -- | 79.88 | -0.4764 | -0.4764 | 0.0053 | 0.0332 | 0.0146 | 2.11 | 9.76 | 7,560.98 | -114.91 | -39.43 | -233.02 | -47.32 | 78.71 | -- | -7,873.23 | -5,261.20 | 1.22 | -32.64 | 0.8641 | -- | 38.27 | -- | -65.47 | -- | -- | -- |
| Journey Medical Corp | 79.18m | -3.85m | 50.58m | 58.00 | -- | 3.44 | -- | 0.6388 | -0.3502 | -0.3502 | 4.19 | 1.05 | 0.8701 | 2.19 | 3.65 | 1,365,190.00 | -4.23 | -- | -10.51 | -- | 66.33 | -- | -4.87 | -- | 1.10 | 0.6863 | 0.4641 | -- | 7.48 | -- | 87.00 | -- | -- | -- |
| Aligos Therapeutics Inc | 13.79m | -99.59m | 51.16m | 67.00 | -- | 0.8627 | -- | 3.71 | -1.51 | -1.51 | 0.1796 | 0.7592 | 0.1105 | -- | -- | 208,969.70 | -79.78 | -51.20 | -98.27 | -59.73 | -- | -- | -722.06 | -1,399.21 | -- | -- | 0.0037 | -- | 11.66 | -- | 8.71 | -- | -62.36 | -- |
Data as of May 16 2024. Currency figures normalised to Reviva Pharmaceuticals Holdings, Inc.'s reporting currency: US Dollar USD
16.45%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 31 Dec 2023 | 1.76m | 6.32% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 994.97k | 3.56% |
| Millennium Management LLCas of 31 Dec 2023 | 801.91k | 2.87% |
| Susquehanna Financial Group LLLPas of 31 Mar 2024 | 242.67k | 0.87% |
| Geode Capital Management LLCas of 31 Dec 2023 | 178.81k | 0.64% |
| Polar Asset Management Partners, Inc.as of 31 Dec 2023 | 154.80k | 0.55% |
| EMC Capital Management LLCas of 31 Dec 2023 | 123.92k | 0.44% |
| The Colony Group LLCas of 31 Dec 2023 | 121.00k | 0.43% |
| Woodline Partners LPas of 31 Dec 2023 | 120.40k | 0.43% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 89.28k | 0.32% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
